Skip to content

Arvinas ARVN Total Liabilities

Total Liabilities at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$155.24M+15.7%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$129.38M-2.0%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$214.51M+81.7%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$16.63M+217%
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$11.18M+21.6%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$25.32M+95.4%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's total liabilities?
Arvinas (ARVN) reported total liabilities of $260.7M in Q1 2026.
How has Arvinas's total liabilities changed year-over-year?
Arvinas's total liabilities decreased by 23.5% year-over-year, from $341M to $260.7M.
What is the long-term trend for Arvinas's total liabilities?
Over 5 years (2020 to 2025), Arvinas's total liabilities has grown at a 30.4% compound annual growth rate (CAGR), from $75.2M to $284M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.